Oxford Science Enterprises

Oxford Science Enterprises (OSE) is a London- and Oxford-based venture capital firm and venture builder that transforms cutting-edge research from the University of Oxford into category-defining companies. With over £1.3 billion in net asset value and a portfolio of more than 50 flagship companies, OSE occupies a unique position as the primary institutional backer of Oxford's world-class science spinouts.

Unlike a typical venture fund that deploys capital into a broad range of sectors, OSE operates a structured Find. Fund. Build. model in deep partnership with Oxford's researchers and Harwell and Culham science campuses. The firm targets companies in deep tech, life sciences, and healthtech that have the potential to solve major global challenges while delivering market-leading returns.

Understanding OSE's model is essential for founders building companies from Oxford research. The firm has backed some of the UK's most successful spinouts, including Exscientia, which completed a $350 million IPO on Nasdaq in 2021, and Barinthus Biotherapeutics, which went public on AIM. OSE has helped deploy more than £3 billion into Oxford spinouts alongside 300 co-investors including blue-chip institutions and sovereign wealth funds.

For founders at the earliest stages, OSE offers something rare: patient capital, deep scientific networks, and hands-on venture-building support. In April 2025, OSE raised a further £175 million ($232 million) from banking partners, demonstrating continued institutional confidence in its model. This guide covers OSE's investment thesis, portfolio composition, check sizes, and practical advice for founders seeking a meeting.

One of the most important things to understand about OSE is that it is not an open-door VC. The firm works almost exclusively with companies that have a demonstrable Oxford, Harwell, or Culham connection. If your company is not founded on Oxford intellectual property or led by Oxford researchers, OSE is likely not the right investor for you.

Oxford Science Enterprises exists to bridge the gap between university research and commercial company formation. Their thesis is straightforward: Oxford produces some of the world's most consequential science, but most of that research sits undeveloped. OSE's role is to find the spinouts worth building, fund them with patient capital, and provide the operational support to scale them into significant businesses.

OSE focuses on three primary verticals: deep tech (including AI, quantum computing, robotics, and industrial technology), life sciences (drug discovery, therapeutics, and genomics), and healthtech (medical devices, diagnostics, and digital health). Within these verticals, the firm looks for companies built on proprietary intellectual property, where Oxford researchers have a meaningful ongoing stake in the business.

The firm's investment philosophy is distinctive in its emphasis on co-creation. OSE does not simply wait for pitch decks to arrive. It works hand-in-hand with researchers to identify commercially promising avenues of inquiry, help design company structures, and assemble founding teams that combine scientific depth with business acumen. This venture-building approach means OSE often becomes involved at the very earliest stages, sometimes before a company is formally incorporated.

In terms of financial return expectations, OSE targets the same outcomes as top-tier venture funds: 10x+ returns through exits via acquisition or public listing. The difference is that OSE's portfolio companies often operate in longer-cycle sectors like drug development or deep tech hardware, requiring more patience than typical software-focused VC.

The firm typically leads or co-leads rounds when investing, particularly at pre-seed and seed stages. As companies mature and approach Series B and beyond, OSE frequently co-invests alongside growth equity funds and crossover investors, particularly for life sciences companies approaching clinical milestones.

OSE's recent fundraise of £175 million in April 2025, backed by Aviva Investors among others, signals continued appetite for their model. The firm has indicated it will continue deploying across pre-seed through growth stages, with particular focus on AI, climate technology, and advanced manufacturing alongside its core life sciences activity.

OSE has maintained a consistent deployment pace in 2024 and 2025, with activity spanning all three core sectors. In early 2026, Stateful Robotics, a deep tech spinout focused on long-horizon AI for robotics, raised a $4.8 million pre-seed round with participation from OSE. The firm has also continued to back existing portfolio companies through subsequent rounds rather than selling down positions prematurely.

On the life sciences side, Wild Bioscience, an Oxford spinout developing climate-resilient wheat varieties, closed a $57 million Series A led by the Ellison Institute with OSE participation. OSE has also been active in AI, with portfolio company Salience Labs (focused on photonic AI chips) advancing toward commercial deployment after its Series A.

The most high-profile exit in recent years remains Exscientia, the AI drug discovery company that IPO'd on Nasdaq in 2021. The company raised more than $525 million in a SoftBank-led round shortly before its IPO, and OSE's early backing translated into a landmark return for the firm. Barinthus Biotherapeutics, formerly Vaccitech, achieved an AIM listing, providing another liquid exit for the portfolio.

Not all OSE investments have succeeded, which is the nature of deep science investing. Base Genomics was acquired by Guardant Health. MiroBio was acquired by Roche. Latent Logic was acquired by Apple. These exits, including the acquisitions, demonstrate that OSE's portfolio companies are attractive acquisition targets for major strategic buyers.

OSE has also expanded its international reach through partnerships, including a 2025 arrangement with Tokyu Land to connect Oxford spinouts with Japan's innovation ecosystem. This kind of cross-border facilitation helps portfolio companies access new markets and co-investors with domain expertise in key sectors.

In terms of deployment pace, OSE typically makes between 8 and 15 new investments per year, with the majority at pre-seed and seed stages. The firm maintains an active core portfolio of approximately 40 companies while managing the full pipeline of older holdings.

OSE's portfolio spans companies at every stage from pre-seed through publicly listed. The diversity of sectors within the portfolio reflects the breadth of Oxford's research strengths, and each company is typically built on a specific breakthrough from an Oxford lab.

In deep tech, Orca Computing has emerged as one of the UK's most advanced quantum computing companies, having raised a Series B to scale its trapped-ion quantum hardware. PQShield is developing post-quantum cryptography solutions, addressing one of the most urgent challenges in enterprise cybersecurity as quantum computing matures. Mind Foundry, an Oxford AI spinout, applies machine learning to industrial and enterprise problems. DiffBlue brings AI-powered code analysis and automated debugging tools to software engineering teams.

In life sciences, Exscientia stands as the most prominent example: an AI-native drug discovery company that designed its first clinical candidate and advanced it to IND filing, all while maintaining one of the most impressive fundraising tracks in European biotech. Grey Wolf Therapeutics is developing a novel approach to cancer immunotherapy. Theolytics is applying phage display to antiviral drug discovery. Sitryx is focused on metabolic disease therapeutics with a novel mechanism of action.

In healthtech, Perspectum has built a suite of AI-powered imaging analytics for liver disease and is scaling commercially across major healthcare systems. Oxford Endovascular is developing next-generation stent technology for treating aneurysms. Ultromics uses AI to improve the accuracy of echocardiograms. Osler Diagnostics is building a point-of-care diagnostics platform.

Several portfolio companies have already exited successfully. YASA, a developer of axial-flux electric motor technology for aerospace and automotive applications, was acquired by a major strategic buyer. Oxford Semantic Technologies, a pioneer in semantic data integration, was acquired by a leading enterprise software company. DJS Antibodies was acquired by a global pharmaceutical company.

One of the most important values OSE provides to portfolio companies is access to their network of 300+ co-investors, potential enterprise customers, and strategic partners. For a deep tech or life science company, this network can dramatically accelerate commercial traction and subsequent fundraising.

OSE evaluates potential investments based on several key criteria that reflect both the nature of science spinouts and the firm's return requirements. Understanding these criteria is essential for founders trying to determine whether OSE is the right investor for their company.

First, Oxford affiliation is non-negotiable. OSE invests almost exclusively in companies founded on intellectual property developed at the University of Oxford or at the Harwell and Culham campuses. The affiliation can take multiple forms: a founder who was a Oxford researcher, a licensing agreement with Oxford's technology transfer office, or an equity stake held by Oxford University Innovation (OUI). If your company does not have a clear Oxford connection, OSE will not be a viable investor.

Second, the underlying science must be genuinely differentiated. OSE looks for companies where the IP is defensible, where the technical barrier to entry is high, and where the science has been de-risked to a point where commercial execution is a realistic near-term possibility. For life sciences companies, this often means evidence of biological validation or a clear path to IND filing. For deep tech companies, it means demonstrated technical performance beyond academic benchmarks.

Third, the founding team matters enormously. OSE has a strong preference for teams that combine scientific founder expertise with at least one operator or business-focused co-founder. Pure academic teams without commercial experience are less attractive unless OSE can actively help recruit business talent into the company. The firm looks for founders who understand both the science and the market opportunity.

Fourth, market size must be large enough to support a significant company. OSE targets returns that require companies to reach substantial scale, which means they prefer markets where the total addressable opportunity is in the hundreds of millions to billions of dollars. A niche tool with a $10 million TAM is unlikely to attract OSE's interest regardless of how interesting the science is.

Fifth, OSE looks for evidence of traction that validates the commercial thesis. For pre-seed companies, this might mean a signed MoU with a potential customer, a prototype that has been tested by target users, or a clear regulatory pathway. For Series A companies, OSE expects more substantial evidence of product-market fit: revenue, LOIs, clinical data, or material partnerships.

Sixth, the path to liquidity optimization must be credible. OSE considers whether a realistic exit pathway exists within a reasonable timeframe. In life sciences, this might mean a clear clinical milestone that would attract pharmaceutical acquirers or enable an IPO. In deep tech, it might mean a strategic acquisition by a large technology company or a vertical SaaS integration that supports a standalone public offering.

Accessing OSE requires a fundamentally different approach than pitching a typical open-door VC. Because OSE operates a venture-building model and works closely with Oxford's research community, the most effective path in is through the university's technology transfer infrastructure rather than cold outreach.

Oxford University Innovation (OUI) is the technology transfer office for the University of Oxford, responsible for commercializing Oxford research. OUI is the primary pipeline through which OSE discovers new investment opportunities. Founders who are spinning out of Oxford should engage with OUI early to understand the IP licensing process and to gain visibility with OSE's investment team.

Warm introductions from Oxford faculty members, researchers, or other portfolio founders are the next most effective path. OSE has deep relationships with the principal investigators whose labs generate the companies in which they invest. A strong endorsement from a recognized Oxford professor carries significant weight in OSE's investment process.

OSE also participates in Oxford's entrepreneurial ecosystem events, including Demo Day formats, showcase events, and the Oxford Venture Capital network. Founders building companies in the Oxford orbit should actively participate in these events to build relationships with OSE partners and principals.

Cold submissions through a website or generic pitch deck are unlikely to succeed at OSE. The firm receives inbound interest from companies without Oxford affiliations, which are automatically screened out. For companies that do have Oxford connections, cold outreach is still a lower-probability path than a network introduction.

For founders who are preparing to approach OSE, the quality of the business case documentation matters. OSE's investment team includes people with deep scientific expertise as well as venture finance experience. Pitch materials should be rigorous, technically accurate, and realistic about milestones and timelines. Deep science companies often require longer development cycles than software startups, and OSE values founders who understand and plan for that reality.

Following up after an initial conversation is expected but should be done thoughtfully. OSE's deal volume means that decision timelines can be longer than at a typical early-stage VC. Founders should send material updates: significant customer wins, new data that de-risks the science, or material changes to the competitive landscape.

While OSE invests in early-stage science companies, they expect founders to have a solid command of their financials. For life sciences companies, this means understanding burn rate, runway, milestone-based spending plans, and the cost of regulatory pathways. For deep tech hardware companies, it means understanding Bill of Materials costs, unit economics at scale, and supply chain dynamics.

Financial preparedness is particularly important when pitching to OSE because deep science investments require more rigorous milestone-based planning than typical software VC. OSE's investment committee will want to understand precisely what each dollar of spend achieves, what the critical experiments or technical milestones are, and what the path to revenue or acquisition looks like over a 5- to 10-year horizon.

Working with a fractional CFO who understands both venture finance and the specific mechanics of science-based companies can meaningfully improve your fundraising odds. Professional financial guidance helps you build credible operating plans, prepare investor-ready financial models, and confidently answer due diligence questions about your burn profile, milestone schedule, and financing runway.

Our team has helped numerous science-based companies prepare for VC fundraising. From milestone-based financial models for life science companies to unit economics frameworks for deep tech hardware companies, we ensure you can present a compelling, rigorous financial case to OSE and other investors.

Founders should also be prepared to discuss intellectual property valuation, licensing fee structures, and any earn-out obligations related to their Oxford IP agreements. OSE's investment team will have due diligence questions about the legal structure of the IP arrangement, and founders who understand these details in depth demonstrate the operational credibility that OSE values.

Understanding your key performance indicators at the company stage you're in is essential. For pre-revenue life sciences companies, this means clinical milestones, IND filing timelines, and regulatory pathway costs. For deep tech companies with early revenue, it means ACV, churn, gross margin, and sales cycle length.

Whether you're preparing to pitch Oxford Science Enterprises or other deep tech-focused investors, having professional financials and a clear milestone plan sets you apart from the competition. Our team has helped science-based startups at every stage understand what institutional investors look for in financial presentations and build the narratives that win rounds.

Exploring other venture capital firms? Our comprehensive collection of VC firm reviews covers hundreds of investors across all stages and sectors.

Each review provides detailed information about investment criteria, portfolio companies, and tips for securing funding. Whether you're looking for seed-stage investors or growth equity firms, you'll find valuable insights in our VC firm guides.

Finding the right investor for your startup is crucial to your success. Take the time to research potential investors and understand their investment thesis before reaching out.

Our guides cover major venture capital firms as well as emerging managers that may be a better fit for your company's specific needs and stage.